Increasing Prevalence of Cardiovascular Diseases to Augment Growth of Acute Heart Failure (AHF) Therapeutics Market
Acute
heart failure is a medical emergency that involves sudden, permanent cessation
of cardiac function (also called ventricular fibrillation). Acute heart failure
most often develops due to a rupture or leaky blood vessel somewhere in the
heart. This can happen either at the heart site itself, such as at the coronary
artery, or at the lung level, such as at the aortic valve. As a result of the
rupture, blood is pooling at the heart site and the blood flow is markedly
reduced. As this pooling continues, blood pressure drops causing a decrease in
cardiac output and, as the problem worsens, shock and death occur.
Market Dynamics
Increasing
prevalence of cardiovascular diseases is expected to propel growth of the
global acute heart failure (AHF) therapeutics market. For instance, according
to the American Heart Association's Heart and Stroke Statistics 2020 Update, by
2035, 45.1% of the U.S population is projected to have some form of cardiovascular
disease. Moreover, increasing geriatric population is also expected to aid in
growth of the market. For instance, according
to United Nations Population Fund, geriatric population in Asia Pacific is
expected to triple between 2010 and 2050 to reach 1.3 billion people by 2050.
High
prevalence of heart failure is also expected to propel growth of the global acute
heart failure (AHF) therapeutics market. For instance, according to the
study, ‘Global epidemiology and future trends of heart failure’, published in
AME Medical Journal in June 2020, heart failure poses the largest burden after
60 years of age and both prevalence and YLDs have increased by 3.9% and 4.5% in
very elderly people during the last 28 years. Moreover, R&D in acute heart
failure (AHF) therapeutics is also expected to aid in growth in the market. For
instance, in November 2020, a clinical trial by Brigham and Women's Hospital
and sponsored by Lexicon Pharmaceuticals, a biopharmaceutical company based in
the U.S., reported that sotagliflozin, a combination sodium/glucose
cotransporter 1 and 2 (SGLT1/2) inhibitor, resulted in a lower risk of the
composite of deaths from cardiovascular causes, hospitalizations for heart
failure, and urgent visits for heart failure than placebo.
Competitive Analysis
Major
players operating in the acute heart failure (AHF) therapeutics market include,
Novartis AG, Cardiorentis AG, Bristol-Myers Squibb Company, Amgen Inc., Bayer
AG, Cytokinetics, Inc., Merck & Company, Inc., Ono Pharmaceutical Co.,
Ltd., and Pfizer Inc., among others.
Comments
Post a Comment